Skip to content

Comparison the effect of daily versus twice weekly usage of iron supplemetation on pregnancy outcomes in nonanemic pregnant women

The single blind clinical trial study of comparing the effect of daily usage of iron complementory to usage of twice a week of it in nonanemic pregnant women on the prenatal and pregnancy outcome (gestational diabetes,preeclampsia,low birth weight)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201202259133N1
Enrollment
508
Registered
2012-05-23
Start date
2012-02-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: gestational diabetes. Condition 2: preeclamsia. Condition 3: low birth weight. Gestational diabetes mellitus NOS Gestational [pregnancy-induced] hypertension with significant proteinuria Disorders related to short gestation and low birth weight, not elsewhere classified

Interventions

Intervention 1: group of receiving daily ferrous sulfate complementery:will receive one tablet(50 mg) dailyfrom the gestational age of 20 weeks till delivery. Intervention 2: group of receiving twice
Prevention
group of receiving daily ferrous sulfate complementery:will receive one tablet(50 mg) dailyfrom the gestational age of 20 weeks till delivery.
group of receiving twice a week ferrous sulfate:will receive one tablet(50 mg) twice a week from the gestational age of 20 weeks till delivery

Sponsors

Tehran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: inclusion criteria: The singletone pregnant women with gestational age of less than 18 weeks, with no history of smoking or usage of glucocorticoid and sympathomymetic drugs, with no history of disease causing polycytemia such as asthma or chronic hypertension, no history of gestational diabetes, preeclapsia or overt diabetes in previous pregnancy, with normal hemoglubin (Hb)11-13.8g/dl and ferritin 10-300 ng/ml. exclusion criteria: In women under study if hemoglubin less than 10.5mg/dl in second trimester and less than 11 mg/dl in third trimester is detected, they will get out of study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Gestational diabetes. Timepoint: one time: at 24-28 weeks of gestation. Method of measurement: Glucose Tolerance Test.;Preeclampsia. Timepoint: first time : 24-28 weeks of gestation, second time : 32-36 weeks of gestation. Method of measurement: measuring blood pressure by manometer .measuring random urine protein measured by urine sampling.;Low birth weight. Timepoint: one time: at birth time. Method of measurement: measuring birth weight of neonate by scale.

Secondary

MeasureTime frame
Side effects of ferrous sulfate such as nausea and vomiting,constipation,metal oral taste. Timepoint: from the prescriping of ferrous sulfate(20 weeks of gestational age till delivery). Method of measurement: answering from paitients.;Hemoglubin and serum ferritin level. Timepoint: first time :<20 weeks and second time : 24-28 weeks and third time: 32 -36 weeks. Method of measurement: measuring the hemoglubin (mg/dl) and serum ferritin (ng/ml) by blood sampling.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Rahimi Sherbaf

Tehran University of Medical Sciences

rahimish@tums.ac.ir+98 21 8890 0002

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026